Development of a Bayesian Forecasting Method for Warfarin Dose Individualisation
暂无分享,去创建一个
[1] G. Levy,et al. Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.
[2] E. Chan,et al. Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic‐pharmacodynamic model , 1994, Clinical pharmacology and therapeutics.
[3] D. Mungall,et al. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation. , 1985, Therapeutic drug monitoring.
[4] Susan Regan,et al. Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.
[5] David C. Anderson,et al. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1996, Archives of internal medicine.
[6] L Aarons,et al. A pharmacokinetic simulation model for ivabradine in healthy volunteers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[7] L. B. Wingard,et al. Pharmacokinetics of warfarin enantiomers: A search for intrasubject correlations , 1978, Clinical pharmacology and therapeutics.
[8] L. Kalra,et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness , 2000, BMJ : British Medical Journal.
[9] D. Berlowitz,et al. Warfarin dose management affects INR control , 2009, Journal of thrombosis and haemostasis : JTH.
[10] M. Pirmohamed,et al. Pharmacogenetics of warfarin: current status and future challenges , 2007, The Pharmacogenomics Journal.
[11] Stephen B. Duffull,et al. The use of simulated annealing for finding optimal population designs , 2002, Comput. Methods Programs Biomed..
[12] R A O'REILLY,et al. STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN. , 1963, The Journal of clinical investigation.
[13] P. Deloukas,et al. A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age , 2010, Clinical pharmacology and therapeutics.
[14] T. Theofanous,et al. Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing. , 1973, Journal of pharmaceutical sciences.
[15] A. Gallus,et al. Assessment of an Age-Adjusted Warfarin Initiation Protocol , 2003, The Annals of pharmacotherapy.
[16] A. Forster,et al. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis , 2007, Canadian Medical Association Journal.
[17] R L Berg,et al. Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing , 2010, Clinical pharmacology and therapeutics.
[18] M. Leaning,et al. Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy. , 1999, British journal of clinical pharmacology.
[19] Janice D Nunnelee,et al. Review of an Article: The international Warfarin Pharmacogenetics Consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360 (8): 753-64. , 2009, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.
[20] J. Vilpo,et al. Poor agreement among prothrombin time international normalized ratio methods: comparison of seven commercial reagents. , 2005, Clinical chemistry.
[21] L B Sheiner,et al. Forecasting individual pharmacokinetics , 1979, Clinical pharmacology and therapeutics.
[22] M. Rieder,et al. Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.
[23] B. Horne,et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.
[24] A. McLachlan,et al. Investigation of the Effects of Herbal Medicines on Warfarin Response in Healthy Subjects: A Population Pharmacokinetic‐Pharmacodynamic Modeling Approach , 2006, Journal of clinical pharmacology.
[25] Malcolm Rowland,et al. Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults , 1993 .
[26] A. Forster,et al. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis , 2008, Canadian Medical Association Journal.
[27] R. Pendleton,et al. Gene-Based Warfarin Dosing Compared With Standard of Care Practices in an Orthopedic Surgery Population: A Prospective, Parallel Cohort Study , 2010, Therapeutic drug monitoring.
[28] Y. Caraco,et al. CYP2C9 Genotype‐guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study , 2008, Clinical pharmacology and therapeutics.
[29] L. Aarons,et al. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[30] M. Moia,et al. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). , 2001, Haematologica.
[31] P. J. Ryan,et al. Computer control of anticoagulant dose for therapeutic management. , 1989, BMJ.
[32] D. Pennell,et al. Cardiovascular magnetic resonance of left ventricular pseudoaneurysm , 2005, Heart.
[33] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[34] W. J. Hamilton,et al. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.
[35] A. Abdelhafiz,et al. Delayed discharges due to initiation of warfarin in atrial fibrillation: a prospective audit. , 2007, The American journal of geriatric pharmacotherapy.
[36] P M Aggeler,et al. Studies on Coumarin Anticoagulant Drugs: Initiation of Warfarin Therapy Without a Loading Dose , 1968, Circulation.
[37] A. Forster,et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. , 2006, Chest.
[38] D. Mungall,et al. Pharmacodynamics of Warfarin at Steady State , 1987, Therapeutic drug monitoring.
[39] L. Aarons,et al. A Bayesian Method Based on Clotting Factor Activity for the Prediction of Maintenance Warfarin Dosage Regimens , 2003, Therapeutic Drug Monitoring.
[40] Peter Wood,et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.
[41] J. Jespersen,et al. Multicentre randomised study of computerised anticoagulant dosage , 1998, The Lancet.
[42] E N Jonsson,et al. A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy , 2007, Clinical pharmacology and therapeutics.
[43] L B Sheiner,et al. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.
[44] R. Day,et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects , 2008, British journal of pharmacology.
[45] L B Sheiner,et al. Computer-aided long-term anticoagulation therapy. , 1969, Computers and biomedical research, an international journal.
[46] R. Gieschke,et al. Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[47] A. Forster,et al. Effect of Study Setting on Anticoagulation Control * , 2006 .
[48] A M Vossepoel,et al. A computer program for long term anticoagulation control. , 1977, Computer programs in biomedicine.
[49] Panos Deloukas,et al. The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.
[50] David G. Covell,et al. Systems and Microcomputer Approach to Anticoagulant Therapy , 1980, IEEE Transactions on Biomedical Engineering.
[51] T J O'Leary,et al. Evaluation of a computer‐assisted method for individualized anticoagulation: Retrospective and prospective studies with a pharmacodynamic model , 1982, Clinical pharmacology and therapeutics.